XORTX to focus on late stage allopurinol intolerant gout program; discussion with FDA planned for first half 2025 regarding ...

FOR centuries, gout has been a deeply misunderstood disease, associated only with jolly, indulgent, and often big men. When Henry VIII was diagnosed, it became firmly entrenched in popular belief ...

CALGARY, Alberta, Jan. 17, 2025 (GLOBE NEWSWIRE) -- ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), ...

Previously, oxypurinol was granted ODD for allopurinol intolerant gout. Dr. Allen Davidoff commented ... levels include three major classes of drugs: (i) oral uricosurics that are used to ...

XORTX to focus on late stage allopurinol intolerant gout program; discussion with FDA planned for first ... The therapeutic options to lower uric acid levels include three major classes of drugs: (i) ...

AZ has been licensing out drugs that don ... of lesinurad and allopurinol, an XOI, and is FDA-approved for the treatment of hyperuricemia associated with gout in patients who have not achieved ...

Colchicine in combination with probenecid or allopurinol is frequently ... The current strategy for managing chronic gout is the use of uric-acid-lowering drugs to reduce urate production or ...

Febuxostat is a second-line option for patients with gout who are unable to take allopurinol due to hypersensitivity ... other highly protein-bound drugs and its potential long-term effects ...